In our previous paper, we reported that myeloid differential primary response protein (MyD88), a key adaptor in the signaling cascade of the innate immune response, inhibits hepatitis B virus (HBV) replication. The MyD88 activated nuclear factor-kappaB (NF-κB) signaling pathway and the intracellular upregulation of NF-κB signaling can induce an antiviral effect. Therefore, the association between the inhibition of HBV replication by MyD88 and NF-κB activation was investigated further. The results show that NF-κB activation was moderately increased after MyD88 expression. The strong activation of NF-κB by the IkappaB kinase complex IKKα/IKKβ dramatically suppressed HBV replication; the MyD88 dominant negative mutant that abrogated NF-κB activity did not inhibit HBV replication. Furthermore, the IκBα dominant negative mutant restored the inhibition of HBV replication by MyD88. These results support a role for NF-κB activation in the inhibition of HBV replication and suggest a novel mechanism for the inhibition of HBV replication by MyD88 protein.
Introduction
Myeloid differential primary response protein (MyD88) has been found to be the primary response gene in M1 myeloblastic leukemia cells induced by IL-6 [1, 2] . Studies have shown that the MyD88 protein is a critical component in the signaling cascade of the innate immune response. MyD88 transduces signals from TIR-containing receptors to the death domaincontaining IL-1R-associated kinases (IRAKs), which lead to the activation of downstream signaling, including NF-κB activation. In our previous study, we showed that MyD88 was induced by IFN-α treatment, and that the expression of MyD88 inhibited hepatitis B virus (HBV) replication; a significant reduction of total and cytoplasmic HBV RNAs at the posttranscriptional level was noted [3] . Since NF-κB is modestly activated by either IFN-α treatment or by MyD88 expression, and NF-κB activation has been shown to interfere with viral replication [4] , this suggests that the inhibition of HBV replication by MyD88 may be mediated via NF-κB activation.
NF-κB is a dimeric transcription factor that has important roles in the regulation of numerous inducible genes involved in the expression of inflammatory cytokines, cell survival, and differentiation [5, 6] . The NF-κB transcription factor can be stimulated by various stimuli, including viral infections, as well as cytokines such as TNF-α and interleukin-1β (IL-1β). These stimuli typically activate the IκBα kinase complex (IKK) that causes the phosphorylation of IκBα at conserved serine residues, which in turn results in its degradation. The degradation of IκBα releases NF-κB, which translocates to the nucleus and initiates targeted gene transcription [7] [8] [9] .
In the present study, we confirmed that the expression of the MyD88 protein can lead to NF-κB activation. The results strongly suggest that the suppression of HBV replication by MyD88 is dependent on NF-κB activity, since abrogation of NF-κB activation by a dominant negative mutant of MyD88 or a superrepressor form of IκBα abolished the suppressive effects of MyD88 on HBV replication. All of these results support the presence of a role for NF-κB signaling activation in the inhibition of HBV replication.
Materials and methods

Cell culture and transfection
Huh7 and HepG2 cells were cultured in DMEM (Gibco-BRL, Grand Island, NY, USA) supplemented with 10% FBS (Gibco-BRL), 2 mM glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin (Gibco-BRL) at 37°C in a humidified CO 2 incubator. Huh7 cells at 70% confluency or HepG2 cells at 30% confluency were transfected with a 3:1 or 5:1 μl:μg ratio of liposomes to DNA (Fugene reagent; Roche, Indianapolis, USA). All transfections were performed using equal total amounts of plasmid DNA normalized with empty vector. The transfection efficiency was normalized by detecting the activity of β-galactosidase in the cell lysates (β-Galactosidase Enzyme Assay KitC; Promega, Madison, USA) after cotransfection with the pSV-β-galactosidase (Promega) vector as the control.
Plasmids and chemicals
pcDNA-MyD88 encoding of the whole transcript of MyD88 has been previously described [3] . Two mutant versions of MyD88 were constructed: truncated M (1-151), encoding amino acids 1 to151 of N-terminal region, and truncated M (152-296), encoding amino acids 152 to the C-terminal end. pHBV3.8 contains a 1.2-copy of the HBV genome (kindly provided by Prof. Wang Yuan, Institute of Biochemistry, Academia Sinica). Plasmid RcCMV-IκBα-SR expresses a superrepressor form of IκBα in which serines 32 and 36 were mutated to alanine [10] . Plasmids pRc-β-actin-3HA-IKKα [11] and -IKKβ [12] were provided by M. Karin, University of California, San Diego. The NF-κB-dependent luciferase reporter plasmid pNF-κB-Luc was obtained from Stratagene Corporation (La Jolla, CA, USA). To monitor the efficiency of transfection, plasmid pRL-TK (Promega), which produces renilla luciferase, was used as an internal control to monitor the efficiency of transfection. SB203580 and PD98059 were obtained from Calbiochem (San Diego, CA, USA).
Real-time PCR analysis of HBV replicative intermediate DNA
HBV replicative intermediate DNA in HBV core particles from transfected cells was analyzed using quantitative real-time PCR as described by Lin et al. [13, 14] . Briefly, Huh7 or HepG2 cells were seeded onto 12-well plates at a density of 2 × 10 5 cells/well. 48 h after transfection, the cells were washed twice with chilled PBS and lysed in 600 μl lysing buffer (10 mmol/l Tris-HCl, pH 7.9, 1 mmol/l EDTA, 1% NP-40, 8% sucrose). After centrifugation at 12,000 rpm for 2 min at 4°C to remove nuclei and debris, the supernatants were collected. To normalize transfection efficiency, supernatants (50 μl) were used to detect the activity of β-galactosidase; 6 μl 1 M magnesium acetate, 12 μl DNase I (5 mg/ ml), and 3 μl RNase A (20 mg/ml) were added to the supernatants, which were subsequently incubated at 37°C for 30 min to digest the remaining DNA and RNA. After centrifugation at 12,000 rpm for 1 min, the supernatants were collected. Next, 16 μl 0.5 M EDTA and 130 μl 35% PEG 8000 in 1.75 M NaCl were added, and the mixture was kept on ice for 1 h to precipitate the core particles. After spinning at 9000 rpm for 5 min, the pellets were re-suspended and again digested with DNase I and then incubated at 37°C for 10 min to ensure full digestion of the remaining DNA that was used for transfection. The re-suspended core particles were then digested with proteinase K, and nucleic acids were extracted and precipitated. At this stage, the DNA was further digested with HpaII to remove plasmid DNA from Escherichia coli. Since DNA methylation occurs at CCGG sequences, viral DNA derived from cells is resistant to this enzyme [15] . A pair of primers flanking one of the six restriction sites of HpaII was used for PCR to ensure that the amplified DNA product was derived from the viral core particles within the transfected cells and was not derived from the remaining plasmid HBV DNA used for transfection. A pair of primers flanking nt 509 was used: HBVF, 5′-GCCCGTTTGTCCTCTAATTCC-3′ (nt 468-488) and HBVR, 5′-GGGAAAGCCCTACGAACCACT-3′ (nt 698-718). The PCR product was 251 bp. Each PCR was carried out in duplicate in a 20-μl volume using FastStart DNA Master SYBR Green I mixture (Roche) for 10 min at 95°C for initial denaturing, followed by 40 cycles of 95°C for 15 s, 56°C for 15 s, and 72°C for 30 s in a LightCycle system (Roche). Detection of the fluorescent product was set at the last step of each cycle. To determine the specificity of amplification, a melting curve analysis was applied to all final PCR products after the cycling protocol. Results are representative of three independent experiments.
Western blot analysis
The cells were washed and harvested at 48 h post-transfection. Cell lysates were separated by SDS-PAGE gel electrophoresis and blotted electrophoretically onto a nitrocellulose membrane (Roche). The membrane was blocked with phosphate-buffered saline (PBS) containing 5% skim milk and then incubated overnight with 1:2000 anti-IκBα (Sigma), 1:2000 anti-phospho-IκBα (Cell signaling), 1:1000 anti-phospho-p38 (Cell signaling), 1:1000 anti-phospho-ERK (Santa Cruz), 1:10000 anti-actin antibody (Sigma), then washed three times in PBST (0.05% Tween 20 in PBS), and incubated with peroxidaseconjugated secondary antibody (1:2000) (Amersham, Buckinghamshire, England) for 1 h. After further washing with PBST, chemiluminescence detection was carried out using ECL detection reagents (Amersham).
ELISA
The HBsAg and HBeAg levels in the supernatants obtained from HBVtransfected Huh7 or HepG2 cells harvested 48 h post-transfection were determined using a standard enzyme-linked immunosorbent assay (ELISA) (Sino-American Biotech). Transfection efficiency was normalized by detecting the activity of the β-galactosidase in the cell lysates. All experiments were performed at least three times.
Immunofluorescence staining
Huh7 or HepG2 cells were seeded onto 12-well plates at a density of 2 × 10 5 cells/well. Each of the plasmids pCDNA-3.1, pcDNA-MyD88 (0.4 μg), and RcCMV-IκBα-SR (0.2 μg) was transiently cotransfected with pHBV3.8 (0.2 μg) into cells. 48 h after transfection, cells were washed with PBS and fixed with 3.7% paraformaldehyde in PBS for 10 min. The cells were permeabilized with 0.2% Triton X-100 in PBS for 5 min at room temperature and incubated in blocking buffer supplemented with 3% BSA (Sigma) for 1 h at room temperature. HBcAg was stained with diluted (1:100) rabbit anti-HBcAg antibody (Dako Co.); goat anti-rabbit-fluorescein isothiocyanate (FITC) or rhodamine-conjugated anti-rabbit secondary antibody was used as the secondary antibody. The nuclei of the cells were counterstained with 10 μg/ml 4′,6′-diamidino-2-phenylindole (DAPI) (Sigma, St. Louis, MO, USA). After incubation with the secondary antibodies, the cells were visualized using a confocal laser scanning microscope.
Luciferase activation assay
To measure report gene activation, Huh7 cells seeded onto 12-well plates at density of 2 × 10 5 cells/well were transiently transfected with NF-κB-dependent luciferase reporter plasmid pNF-κB-Luc (0.2 μg) alone, or together with other plasmids. To monitor transfection efficiency, pRL-TK (0.02 μg) was added to each well. The cells were lysed and analyzed for luciferase and renilla luciferase activity (Promega). The results are reported as the normalized mean ± S.D.
Results
MyD88-mediated suppression of HBV replication is independent of p38 MAPK and ERK1/2 signaling
Since expression of MyD88 activates NF-B and MAPK family members, including ERK, p38, and JNK, we first investigated whether the MAPK and ERKs play important roles in the suppressive effect of MyD88 on HBV replication. Huh7 cells were transfected with MyD88-expressing plasmid. The total IκBα and the phosphorylated active form of IκBa, p38, and ERK1/2 were assessed with Western blot analysis. As shown in Fig. 1A , in addition to the degradation of IκBα, increased phosphorylation of IκBα, p38 and ERK1/2 was observed in MyD88 transfected cells. To determine if these signaling cascades are required for the suppression of HBV replication by MyD88, SB203580, a specific inhibitor of p38 MAPK, and PD98059, a specific inhibitor of ERK1/2, were used. Results showed that, after the addition of SB203580, although phosphorylation of p38 was effectively blocked by SB203580 at 10 μM (Fig. 1D) , the overexpression of MyD88 still significantly suppressed HBV protein synthesis and DNA replication (Fig. 1B) . Similar results were obtained in the presence of 20 μM PD98059. As shown in Fig. 1C , the reduction in the HBV HBsAg or HBeAg as well as core particle DNA levels by MyD88 could not be altered by 20 μM PD98059, although phosphorylation of ERK1/2 activated by MyD88 was effectively blocked by PD98059 at 20 μM (Fig. 1D) . Taken together, these results indicate that neither p38 MAPK nor ERK1/2 is required for the MyD88-mediated antiviral effect against HBV.
NF-κB activation is essential for MyD88-mediated suppression of HBV
In order to determine whether the NF-κB signaling pathway is involved in the inhibition of HBV by MyD88, truncated versions encoding the MyD88 NH2 terminal region [M (1-151)] and the MyD88 dominant negative region [M (152-296)] were constructed. Luciferase activity assay showed that, while the expression of the full-length MyD88 (M-full) in Huh7 cells resulted in the activation of NF-κB activity and M (1-151) was still capable of inducing NF-κB activity, albeit to a lesser extent, M (152-296) did not induce NF-κB activity ( Fig. 2A) .
To confirm if the NF-κB activity that is induced by MyD88 is essential for the inhibition of HBV replication, Huh7 and HepG2 cells were transiently transfected with pHBV3.8 and Mfull, M (1-151), and M (152-296). Compared with M-full transfected Huh7 cells, the expression of M (1-151) still led to a reduction of viral protein synthesis and core particle-associated HBV DNA (Fig. 2B) . However, the expression of MyD88 dominant negative M (152-296) did not have an inhibitory effect on HBV replication. In HepG2 cells, similar results were obtained (Fig. 2C) .
Blockage of NF-κB activation abolishes MyD88-mediated suppression of HBV
To block NF-κB activation, plasmid IκBα-SR was used. Plasmid IκBα-SR, in which Ser32 and Ser36 residues critical for phosphorylation by IKK are replaced by alanine and express the superrepressor form of IκBα, was used. The Huh7 cells were transfected with HBV DNA, plasmid M-full, or with a different dose of plasmid IκBα-SR. Similar to the results described above, after the expression of MyD88, a reduction of 67% was observed with HBeAg and a reduction of 78% with HBsAg was observed. However, in the culture supernatants, the co-expression of IκBα-SR led to a dose-dependent accumulation of 69%, 72%, and 96%, respectively, for HBeAg, and of 61%, 75%, and 92%, respectively, for HBsAg (Fig. 3A) . This indicates that MyD88 inhibition of HBV replication was disturbed. Immunostaining was done to detect the presence of core protein in these cells. As shown in Fig. 3C , the co-expression of MyD88 significantly reduced core protein synthesis. However, the co-expression of IκBα-SR dramatically restored the core protein level; the results were consistent with IκBα-SR's effect on HBeAg and HBsAg. The real-time PCR analysis of HBV replicative intermediate DNA supported the above results (Fig. 3A) . With HepG2 cells, similar results were obtained (Fig. 3B, C) .Taken together, these results strongly indicate that the MyD88-mediated suppression of HBV is dependent on NF-κB activation.
NF-κB activation alone is sufficient to inhibit HBV replication
To further determine the role of NF-κB activation in the inhibition of HBV by MyD88, we investigated whether the activation of NF-κB alone could inhibit HBV replication. The cotransfection of 0.1 μg of IKKα/IKKβ with the HBV genome into Huh7 cells resulted in a 30% reduction of HBeAg and a 25% reduction of HBsAg (Fig. 4A) . This reduction was even more substantial if the amount of IKKα/IKKβ was increased to 0.4 μg; similar results were obtained when HBV core particle DNA was measured (Fig. 4B) . Thus, the above results further support a role for NF-κB in the inhibition of HBV replication.
Discussion
Our previous studies revealed that MyD88, a key adaptor in the signaling cascade of the innate immune response, can inhibit hepatitis B virus (HBV) replication. NF-κB activation was observed after the overexpression of MyD88, and the intracellular upregulation of NF-κB signaling could induce an antiviral effect. Therefore, in the present study, the association between the inhibition of HBV replication by MyD88 and NF-κB activation was further investigated. First, we found that the suppression of the HBV RNA level was independent of the p38 MAPK and ERK1/2 signaling pathway (Fig. 1) . Second, overexpression of MyD88 triggers the activation of NF-κB ( Fig. 2A) and promotes nuclear translocation of the p65 subunit of NF-κB (data not shown). Third, the expression of a mutant form of IκBα, which abrogates the NF-κB activity that is mediated by MyD88, abolished the suppressive effect of MyD88 on HBV (Fig. 3) . Fourth, the strong activation of NF-κB signaling by the co-expression of IKKα/IKKβ alone was sufficient to inhibit hepatitis B virus replication (Fig. 4) .Taken together, these results indicate that the inhibition of HBV replication by MyD88 occurs through an NF-κB-dependent pathway, and that the NF-κB signaling pathway functions as a crucial mediator of MyD88's antiviral effect against HBV.
NF-κB has been identified as a central regulator of host immune and inflammatory responses. Studies have suggested that the host utilizes NF-κB to trigger defense mechanisms against viral pathogens. Mice deficient in different members of the NF-κB family are more susceptible to infection [16] [17] [18] . Vaccinia virus A52R effectively mimics the effect of the dominant-negative form of MyD88 and abrogates the IL-1-mediated induction of NF-κB, which is important for resistance to vaccinia virus [19] . TNF-alpha was reported to suppress hepatitis B virus DNA replication by disrupting the formation or the stability of cytoplasmic viral capsids through a pathway that requires NF-κB activation [20] . Furthermore, NF-κB activation was reported to drive an antiviral response in human cytomegalovirus (HCMV)-infected cells, and interferon-β was identified as the responsible factor [4] . Our data show that MyD88 has evolved the same strategies to exploit NF-κB activation to dramatically inhibit HBV replication. Thus, the triggering of NF-κB activation may be a common strategy utilized by the host to activate the host immune response that is required for controlling viral infections. There is evidence that NF-κB activation can initiate the transcription of a number of cellular antiviral genes. To identify the NF-κB-responsive gene(s) that may play a key role in the antiviral action of MyD88, the levels of selected inflammatory and antiviral genes, including IFN-β, IFN-γ, IL-6, TLR2, and TLR9, were analyzed in MyD88-expressing Huh7 cells; however, no changes were detected (data not shown). Further research is required to identify the cellular genes that are activated by NF-κB to downregulate HBV transcripts so that a more precise molecular understanding of MyD88's antiviral action can be developed.
It has been reported that many viruses use activated NF-κB for survival. For example, HBV X targets the NF-κB/IκBα complex, causing the activation of NF-κB, which can promote reverse transcription of pgRNA and viral DNA replication [21] [22] [23] [24] . However, in the present study, the activation of NF-κB was found to be detrimental to HBV replication. It is possible that the molecular mechanisms by which MyD88 or HBV activate the NF-κB pathway are different. This may account for the equilibrium that has been noted between the host and the HBV with respect to NF-κB activation [25] ; this issue should be studied further.
In addition to activating NF-κB signaling, although coexpression of MyD88 could lead to the activation of p38 MAPK and ERK (Fig. 1A) , results showed that MyD88-mediated suppression of HBV replication was independent of p38 MAPK and ERK1/2 signaling (Fig. 1B, C) . It has been reported that there is correlation between MAPK, the ERK signaling pathway and HBV replication [26, 27] . For example, the multifunctional HBx protein was found to be important for viral infection. In the cytoplasm, HBx activates cellular signaling pathways, such as Ras, Src, and c-Jun NH2-terminal kinase (JNK), MAPK and phosphatidylinositol 3-kinase (PI-3K) signal transduction pathways and that is thought to be important for viral reverse transcription, transcriptional activation, DNA replication and the HBV core assembly [26, [28] [29] [30] [31] . It was also reported that HBx induces the activation of p38 MAPK and the inhibition of p38 kinase activity by SB203580-attenuated HBx-induced mitochondrial clustering [23] . Besides, activated ERK1/2 has been shown to inhibit HBV replication [32, 33] . However, no relationship between their activation and the inhibitory effects of MyD88 on HBV replication was established. This could be due to the differences in the degree of activation of ERK and MAPK signaling by MyD88 and activated Ras [32] .
It has been reported that poly(I·C) inhibits HBV replication by inducing interferon-α/β [34] and study in transgenic mice showed that HBV replication was significantly abolished by the administration of ligands specific for TLR3, TLR4, TLR5, TLR7, and TLR9 in an interferon-α/β-dependent manner [35] , all of which suggested that inhibition of HBV replication by the TLR ligands was associated with the production of interferon-α/β. Since IFN-α inducible MyD88 is a key adaptor of TLR signaling, it is reasonable to test whether there was an involvement of TLR signaling pathway in MyD88-mediated anti-HBV replication. However, no significant production of IFN-α/β as well as the activation of interferon signaling were observed in MyD88 overexpressing cells (data not shown). One possibility is that TLRs are not highly expressed in Huh7 or HepG2 cells (data not shown). Another reason may be that TLR ligands did not activate an antiviral program by targeting the hepatocytes directly [35] and worthy to be further investigated.
In conclusion, this study confirmed that MyD88 has inhibitory activity on HBV gene replication and further demonstrated that the anti-HBV effect exerted by MyD88 is mediated by the activation of the NF-κB signaling pathway. Studies are ongoing to investigate the precise mechanism involved in MyD88's antiviral effect against HBV, such as the identification of inhibitory factor(s), which may lead to new approaches for controlling chronic HBV infection. 
